Clinical trial
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
NCT00296062 · Case Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00296062 |
|---|---|
| Title | Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer |
| Official title | Dose-Dense and Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in Solid Tumors and Phase II With Bevacizumab a First-Line Therapy of Advanced Colorectal Cancer |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, capecitabine, irinotecan hydrochloride, oxaliplatin |
| Enrollment | 12 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | May 1, 2011 |
| First posted | Feb 24, 2006 |
| Last update posted | Jan 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: